Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : NNVC - NanoViricides, Inc. -- Ignore unavailable to you. Want to Upgrade?

To: HardToFind who wrote (11970)	2/27/2019 7:25:32 PM
From: old 'n cranky	Read Replies (1) \| Respond to of 12873

Did they hide em in the first paragraph? announced today that it has entered into a securities purchase agreement with certain institutional investors providing for the purchase and sale of 6,944,446 units at a price of $0.36 per unit. Each unit comprises 1 share of common stock and 1 five-year warrant exercisable at $0.61.

To: HardToFind who wrote (11970)	2/27/2019 7:37:40 PM
From: old 'n cranky	Respond to of 12873

Both (share sale and license) require 8-k filing(s). Due within 4 business days of the "event". That's Tuesday for the share sale. I don't think that the pr says when the Company "reached an agreement on the terms of the license for the drug development against VZV" but I don't want to read it again to be sure. Perhaps the 8-K itself will have to clear that up. I expect it by Monday...

To: HardToFind who wrote (11970)	2/27/2019 8:41:00 PM
From: old 'n cranky	Read Replies (1) \| Respond to of 12873

I can't believe what I just read: including a 15% royalty on sales (net of costs) That is absolutely mind-boggling. Here's the way it appears to me: There was some question in your mind about what the term "net sales" meant as it appeared in the "previous" amended license. I told you in no uncertain terms what net sales meant to virtually every accountant and honest lawyer on the planet...it's simply the dollar value of billings for goods and services less any deductions for returns, allowances or discounts. It is distinguished from "net profits" by the fact that the net profit is derived by the deduction of the costs of materials and labor, if any, required to make the goods sold and overhead costs such as rents, salaries, professional fees, R&D, office supplies...operating costs. You asked for a clarification at the shareholder meeting and the response you got should probably be reviewed. Now look at what Emperor Diwan has done. Unless I'm imagining things he's taken advantage of this opportunity to pretend that the term "net sales" in the existing Amended Agreement really means "sales (net of costs)". Muddying up the waters. It's shameful. Even if it doesn't come up until some day years down the road, perhaps in a case brought by some downtrodden lead plaintiff shareholder, people should know what the real deal is NOW. You were obviously very right to ask what the term meant. You might want to do it again and get the understanding in writing somehow, because 15% of "sales (net of costs)" can be expected to be a helluva lot less than "net sales". Just in case there are any sales it's the kind of thing that should be cleared up ahead of time and right now it's a moving target..